Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026284 | 0.75 | SMN1; SMN2 (0.46) | HTTKDM4EALDH1A1LMNAGAA | |
| SCHEMBL846320 | 0.75 | KDM4E (0.42) | HTTKDM4EALDH1A1LMNAGAA | |
| SCHEMBL29377550 | 0.75 | KDM4E (0.42) | HTTKDM4EALDH1A1LMNAGAA | |
| SCHEMBL29478590 | 0.75 | SMN1; SMN2 (0.46) | HTTKDM4EALDH1A1LMNAGAA | |
| SCHEMBL30695898 | 0.74 | LIMK1 (0.30) | — | |
| SCHEMBL1210409 | 0.74 | LIMK1 (0.30) | — | |
| SCHEMBL2054542 | 0.74 | WNT3A (0.33) | MAP3K14DRD2 | |
| SCHEMBL27202528 | 0.74 | SMN1; SMN2 (0.45) | HTTKDM4EALDH1A1LMNA | |
| SCHEMBL20614676 | 0.74 | — | — | |
| SCHEMBL29618376 | 0.72 | LMNA (0.37) | HTTKDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| US-10407440-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3378860-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-09-26 | — | — | EP | disclosed |
| EP-2433938-B1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9714257-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| EP-2474544-B1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-12 | — | — | EP | disclosed |
| EP-2474543-B1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-9249135-B2 | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2474544-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474543-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433938-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | TPH1, HDAC1, HDAC2 | MAP3K14 3329/4885HTT 682/4885TNF 2961/4885 |
| US-10407440-B2 | Therapeutic agent for motor disorders | DDT, COMT, SLC6A3 | MAP3K14 2652/4885HTT 41/4885TNF 4443/4885 |
| US-20170275296-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | MAP3K14 2652/4885HTT 41/4885TNF 4443/4885 |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | MAP3K14 3617/4885HTT 969/4885TNF 4579/4885 |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | MAP3K14 2652/4885HTT 41/4885TNF 4443/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | MAP3K14 3617/4885HTT 969/4885TNF 4579/4885 |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | MAP3K14 3617/4885HTT 969/4885TNF 4579/4885 |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | MAP3K14 2652/4885HTT 41/4885TNF 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.